This year’s BioPort Atlantic life sciences conference will include a venture capital panel discussion, as well as a pair of pitch sessions featuring pre-seed and seed-stage startups from the region.
When BioPort attendees gather at the Halifax Marriot September 19, the VC panel will feature investors from firms such as Vancouver-based Pender Ventures and Quebec specialist fund AmorChem.
The startup pitches, meanwhile, will be moderated by George Kenney, a life sciences entrepreneur who co-founded Boston-based EntraTympanic.
“Explore the evolving landscape of life science investments with a detailed analysis of trends since the peak year of 2021,” promises conference organizer Life Sciences Nova Scotia. “Gain a forward-looking perspective on investment strategies and the innovation potential within this dynamic industry."
Here’s a look at the pitching companies:
PRE-SEED
Halifax
Brightlight sells AI tools for patient intake and management to enterprise clients in the healthcare space.
Halifax
Elle MD plans to market a novel birth control device that does not rely on hormonal treatment.
Halifax
ResolveHD has developed an AI system that uses natural language processing to read and clean up disorganized medical records.
Grates Cove, N.L.
7 Fathoms makes seaweed-based health products.
SEED-STAGE
St. John’s
Amp has developed an app that aims to use artificial intelligence and behavioural modification to help pre-diabetic people avoid becoming fully diabetic.
St. John’s
Granville designs and prints three-dimensional, anatomically correct models of women’s pelvises for use as educational tools.
Halifax
Kardio Diagnostix is developing an artificial intelligence system to help doctors assess whether a cardiac murmur is caused by a heart defect.
Halifax
SoundBlade is developing a surgical technique to use sonic energy to cut tissue, which has applications including a surgery to treat sleep apnea.
